JP4172598B2 - 結核菌由来の核酸フラグメント及びポリペプチドフラグメント - Google Patents

結核菌由来の核酸フラグメント及びポリペプチドフラグメント Download PDF

Info

Publication number
JP4172598B2
JP4172598B2 JP54107498A JP54107498A JP4172598B2 JP 4172598 B2 JP4172598 B2 JP 4172598B2 JP 54107498 A JP54107498 A JP 54107498A JP 54107498 A JP54107498 A JP 54107498A JP 4172598 B2 JP4172598 B2 JP 4172598B2
Authority
JP
Japan
Prior art keywords
sequence
seq
polypeptide
nucleic acid
information
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP54107498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515359A5 (https=
JP2001515359A (ja
Inventor
アンデルセン，ペーター
スクジョト，リッケ
ローゼンクランツ，イーダ
ヴェルディング，カーリン
ラースムセン，ペータ，ビアク
エティンガ，トマス
フロリオ，ヴァルタ
Original Assignee
スタテンス セールム インスティトゥート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スタテンス セールム インスティトゥート filed Critical スタテンス セールム インスティトゥート
Publication of JP2001515359A publication Critical patent/JP2001515359A/ja
Publication of JP2001515359A5 publication Critical patent/JP2001515359A5/ja
Application granted granted Critical
Publication of JP4172598B2 publication Critical patent/JP4172598B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
JP54107498A 1997-04-02 1998-04-01 結核菌由来の核酸フラグメント及びポリペプチドフラグメント Expired - Lifetime JP4172598B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DK37697 1997-04-02
US4462497P 1997-04-18 1997-04-18
US60/044,624 1997-04-18
DK127797 1997-11-10
US7048898P 1998-01-05 1998-01-05
US60/070,488 1998-01-05
US1277/97 1998-01-05
US0376/97 1998-01-05
PCT/DK1998/000132 WO1998044119A1 (en) 1997-04-02 1998-04-01 NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2007299636A Division JP4406024B2 (ja) 1997-04-02 2007-11-19 結核菌由来の核酸フラグメント及びポリペプチドフラグメント
JP2008131389A Division JP4544434B2 (ja) 1997-04-02 2008-05-19 結核菌由来の核酸フラグメント及びポリペプチドフラグメント

Publications (3)

Publication Number Publication Date
JP2001515359A JP2001515359A (ja) 2001-09-18
JP2001515359A5 JP2001515359A5 (https=) 2008-07-10
JP4172598B2 true JP4172598B2 (ja) 2008-10-29

Family

ID=47018662

Family Applications (4)

Application Number Title Priority Date Filing Date
JP54107498A Expired - Lifetime JP4172598B2 (ja) 1997-04-02 1998-04-01 結核菌由来の核酸フラグメント及びポリペプチドフラグメント
JP2007299636A Expired - Lifetime JP4406024B2 (ja) 1997-04-02 2007-11-19 結核菌由来の核酸フラグメント及びポリペプチドフラグメント
JP2008131389A Expired - Lifetime JP4544434B2 (ja) 1997-04-02 2008-05-19 結核菌由来の核酸フラグメント及びポリペプチドフラグメント
JP2010002535A Withdrawn JP2010154856A (ja) 1997-04-02 2010-01-08 結核菌由来の核酸フラグメント及びポリペプチドフラグメント

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2007299636A Expired - Lifetime JP4406024B2 (ja) 1997-04-02 2007-11-19 結核菌由来の核酸フラグメント及びポリペプチドフラグメント
JP2008131389A Expired - Lifetime JP4544434B2 (ja) 1997-04-02 2008-05-19 結核菌由来の核酸フラグメント及びポリペプチドフラグメント
JP2010002535A Withdrawn JP2010154856A (ja) 1997-04-02 2010-01-08 結核菌由来の核酸フラグメント及びポリペプチドフラグメント

Country Status (10)

Country Link
EP (2) EP0972045A1 (https=)
JP (4) JP4172598B2 (https=)
AT (1) ATE370236T1 (https=)
AU (1) AU740545B2 (https=)
CA (1) CA2285625C (https=)
DE (1) DE69838268T2 (https=)
DK (1) DK1449922T3 (https=)
ES (1) ES2291810T3 (https=)
PT (1) PT1449922E (https=)
WO (1) WO1998044119A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
CA2319380A1 (en) * 1997-11-10 1999-05-20 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from m. tuberculosis
CA2322505A1 (en) * 1998-03-06 1999-09-10 Statens Serum Institut Production of mycobacterial polypeptides by lactic acid bacteria
AU2594500A (en) * 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
ATE429245T1 (de) * 1999-05-04 2009-05-15 Univ New Jersey Med Durch mycobacterium tuberculosis und nicht durch bcg exprimierte proteine und ihre verwendung als diagnostische reagenzien und impfstoffe
US6537552B1 (en) 1999-10-19 2003-03-25 Iowa State University Research Foundation Vaccine adjuvant
EP1278769A2 (en) * 2000-04-19 2003-01-29 Statens Serum Institut Tuberculosis antigens and methods of use thereof
US7288261B2 (en) * 2000-07-10 2007-10-30 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
WO2004099771A1 (en) 2003-05-08 2004-11-18 Statens Serum Institut A new specific epitope based immunological diagnosis of tuberculosis
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
EP2441493B1 (en) 2006-03-14 2014-05-07 Oregon Health and Science University Methods for producing an immune response to tuberculosis
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
CA2668100C (en) 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
CA2769645A1 (en) * 2009-07-29 2011-02-03 Bernd Helmut Adam Rehm Polymer particles and uses thereof
WO2011159814A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Novel live recombinant booster vaccine against tuberculosis
IN2014DN08675A (https=) * 2012-04-16 2015-05-22 Aeras Global Tb Vaccine Found
CN104897838B (zh) * 2015-06-10 2016-08-17 重庆医科大学 一种强极性有机酸碱混合物的同时提取分离分析方法
US20220213461A1 (en) * 2019-05-07 2022-07-07 Nanyang Technological University Asx-specific protein ligases and uses thereof
CN113373162A (zh) * 2020-03-09 2021-09-10 北京蛋白质组研究中心 结核分枝杆菌H37Rv新基因Rv0229A及其编码蛋白和应用
CA3176303A1 (en) * 2020-04-20 2021-10-28 Antonio FACCIUOLO Compositions and methods for preventing, controlling and diagnosing mycobacterial infections
CN116082514B (zh) * 2021-11-05 2024-02-13 安博智联(北京)生物科技有限公司 结核分枝杆菌特异性的重组融合蛋白em及其应用
WO2025250534A1 (en) * 2024-05-28 2025-12-04 The Board Of Trustees Of The Leland Stanford Junior University T cell targets for tuberculosis vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK79893D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
JPH11506320A (ja) * 1995-05-23 1999-06-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 豊富な細胞外産物、ならびにそれらを産生および使用するための方法
DE69636075D1 (de) * 1995-09-01 2006-06-01 Corixa Corp Verbindungen und verfahren zur diagnose von tuberkulose
TR200901109T1 (tr) * 1995-09-01 2012-02-21 Corixa Corporation Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler

Also Published As

Publication number Publication date
CA2285625C (en) 2015-06-30
DE69838268D1 (de) 2007-09-27
JP2010154856A (ja) 2010-07-15
JP2008301817A (ja) 2008-12-18
EP1449922B1 (en) 2007-08-15
ES2291810T3 (es) 2008-03-01
EP1449922A2 (en) 2004-08-25
EP0972045A1 (en) 2000-01-19
AU740545B2 (en) 2001-11-08
JP2008142079A (ja) 2008-06-26
PT1449922E (pt) 2007-11-09
WO1998044119A1 (en) 1998-10-08
JP2001515359A (ja) 2001-09-18
AU6820498A (en) 1998-10-22
JP4406024B2 (ja) 2010-01-27
DK1449922T3 (da) 2007-12-03
ATE370236T1 (de) 2007-09-15
DE69838268T2 (de) 2008-05-08
CA2285625A1 (en) 1998-10-08
EP1449922A3 (en) 2004-11-17
JP4544434B2 (ja) 2010-09-15

Similar Documents

Publication Publication Date Title
JP4406024B2 (ja) 結核菌由来の核酸フラグメント及びポリペプチドフラグメント
US6991797B2 (en) M. tuberculosis antigens
AU750173B2 (en) Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
US5955077A (en) Tuberculosis vaccine
US8076469B2 (en) TB diagnostic based on antigens from M. tuberculosis
EP0706571B1 (en) Tuberculosis vaccine
US6641814B1 (en) Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
JP5010079B2 (ja) マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法
US20040013685A1 (en) Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
EP1117683A2 (en) Tb vaccine and diagnostic based on antigens from the m. tuberculosis cell
JP5075969B2 (ja) マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法
EP1484405A1 (en) Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis
AU2011200353A1 (en) Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070726

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071018

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080519

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080418

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080729

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080807

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110822

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120822

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130822

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term